FibroGen Status
The company (NAS: FGEN) received an undisclosed amount of development capital from Foresite Capital Management on June 30, 2017 through a private placement.
Developer of therapeutics for addressing fibrotic disorders. The company discovers, develops and commercializes therapeutics aimed at stopping fibrosis, pathological scarring, addressing needs of fibrotic disorders affecting major organs, diabetes, surgical procedures and fibroproliferative tumor progression and metastasis.
Year Founded
1993
Employees
423
RevenueTTM 3Q2018
$147.4 M
General Information
-
Website
-
Business Status
Generating Revenue
-
Ownership Status
Publicly Held
-
Financing Status
Formerly VC-backed
FibroGen News and Updates
Myocardial Infarction Drug – Industrial IT
Industrial IT | May 28, 2022
FibroGen, Inc. (NASDAQ:FGEN) Expected to Announce Quarterly Sales of $36.60 Million
Defense World | May 26, 2022
Global Idiopathic Pulmonary Fibrosis Market Top Countries Analysis 2022-2029 | FibroGen, Promedior, Merck – Carbon Valley Farmer and Miner
Carbon Valley Farmer and Miner | May 26, 2022
FibroGen to Present at Jefferies Healthcare Conference
Yahoo Finance | May 26, 2022
FibroGen's Verticals
FibroGen Primary Industry Sector / Group / Code
FibroGen's Trends
FibroGen Metrics
Growth Rate
SimilarWeb Unique Visitors
Majestic Referring Domains
Headquarters
-
HQ Address Line 1409 Illinois Street
-
HQ CitySan Francisco
-
HQ State/ProvinceCalifornia
-
HQ Post Code94158
-
HQ CountryUnited States
FibroGen's Keywords
mood_badFeed is empty.
Add a review